{
    "root": "96765b43-a41f-4bba-a582-0e130e813ad3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Paliperidone"
    },
    "value": "20250221",
    "ingredients": [
        {
            "name": "PALIPERIDONE",
            "code": "838F01T721"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "CELLULOSE ACETATE",
            "code": "3J2P07GVB6"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "paliperidone extended-release tablets atypical antipsychotic agent indicated treatment schizophrenia ( 1.1 ) adults : efficacy established three 6-week trials one maintenance trial . ( 14.1 ) adolescents ( ages 12 17 ) : efficacy established one 6-week trial . ( 14.1 ) treatment schizoaffective disorder monotherapy adjunct mood stabilizers and/or antidepressants . ( 1.2 ) efficacy established two 6-week trials adult patients . ( 14.2 )",
    "contraindications": "initial dose recommended dose maximum dose schizophrenia - adults ( 2.1 ) 6 mg/day 3 12 mg/day 12 mg/day schizophrenia - adolescents ( 2.1 ) weight < 51 kg 3 mg/day 3 6 mg/day 6 mg/day weight \u2265 51kg 3 mg/day 3 12 mg/day 12 mg/day schizoaffective disorder - adults ( 2.2 ) 6 mg/day 3 12 mg/day 12 mg/day tablet swallowed whole chewed , divided , crushed . ( 2.3 )",
    "warningsAndPrecautions": "paliperidone extended-release tablets available following strengths packages . tablets round-shaped . 1.5 mg tablets brown colored , round , biconvex , film-coated tablet release portal one side \u2018 pl1 \u2019 imprinting black ink either side tablets , available bottles 30 child resistant closure ( ndc 27241-276-30 ) . 3 mg tablets white off-white colored , round , biconvex , film-coated tablet release portal one side \u2018 pl2 \u2019 imprinting black ink either side tablets , available bottles 30 child resistant closure ( ndc 27241-277-30 ) 6 mg tablets yellow colored , round , biconvex , film-coated tablet release portal one side \u2018 pl3 \u2019 imprinting black ink either side tablets , available bottles 30 child resistant closure ( ndc 27241-278-30 ) 9 mg tablets pink colored , round , biconvex , film-coated tablet release portal one side \u2018 pl4 \u2019 imprinting black ink either side tablets , available bottles 30 child resistant closure ( ndc 27241-279-30 ) . storage handling store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] . protect moisture . keep reach children .",
    "adverseReactions": "paliperidone contraindicated patients known hypersensitivity either paliperidone risperidone , excipients paliperidone formulation . hypersensitivity , including anaphylactic angioedema , reported patients treated risperidone patients treated paliperidone . paliperidone metabolite risperidone .",
    "indications_original": "Paliperidone extended-release tablets are an atypical antipsychotic agent indicated for Treatment of schizophrenia ( 1.1 ) Adults: Efficacy was established in three 6-week trials and one maintenance trial. ( 14.1 ) Adolescents (ages 12 to 17): Efficacy was established in one 6-week trial. ( 14.1 ) Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. ( 1.2 ) Efficacy was established in two 6-week trials in adult patients. ( 14.2 )",
    "contraindications_original": "Initial Dose Recommended Dose Maximum Dose Schizophrenia - adults ( 2.1 ) 6 mg/day 3 to 12 mg/day 12 mg/day Schizophrenia - adolescents ( 2.1 ) Weight < 51 kg 3 mg/day 3 to 6 mg/day 6 mg/day Weight \u2265 51kg 3 mg/day 3 to 12 mg/day 12 mg/day Schizoaffective disorder - adults ( 2.2 ) 6 mg/day 3 to 12 mg/day 12 mg/day Tablet should be swallowed whole and should not be chewed, divided, or crushed. ( 2.3 )",
    "warningsAndPrecautions_original": "Paliperidone extended-release tablets are available in the following strengths and packages. All tablets are round-shaped.\n                  \n                  1.5 mg tablets are brown colored, round, biconvex, film-coated tablet with release portal on one side and \u2018PL1\u2019 imprinting with black ink on either side of the tablets, and are available in \n                  Bottles of 30 with child resistant closure\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (NDC 27241-276-30).\n                  \n                  3 mg tablets are white to off-white colored, round, biconvex, film-coated tablet with release portal on one side and \u2018PL2\u2019 imprinting with black ink on either side of the tablets, and are available in \n                  Bottles of 30 with child resistant closure\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (NDC 27241-277-30)\n                  \n                  6 mg tablets are yellow colored, round, biconvex, film-coated tablet with release portal on one side and \u2018PL3\u2019 imprinting with black ink on either side of the tablets, and are available in \n                  Bottles of 30 with child resistant closure\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (NDC 27241-278-30)\n                  \n                  9 mg tablets are pink colored, round, biconvex, film-coated tablet with release portal on one side and \u2018PL4\u2019 imprinting with black ink on either side of the tablets, and are available in \n                  Bottles of 30 with child resistant closure \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 (NDC 27241-279-30).\n                  \n                     \u00a0\n                  \n                  \n                     Storage and Handling\n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); excursions permitted to 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture.\n                  \n                  \u00a0Keep out of reach of children.",
    "adverseReactions_original": "Paliperidone\u00a0is contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone."
}